European Federation of Pharmaceutical Industries and Associations (EFPIA)
This sponsor has funded 5 studies across 10 countries.
This sponsor has funded 5 studies across 10 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 11157 | Finalised | Identification of type 2 diabetes cases in a set of databases participating to the EMIF project | Yes | No |
| 14060 | Ongoing | Estimating prevalence and incidence of acute myocardial infarction in a set of heterogeneous sources of observational health data collaborating in the... | Yes | No |
| 24458 | Ongoing | EMIF Use Case 17 - Investigating the relationship in paediatric population between dosing of antibiotics (prescribed, dispensed or administered) and... | Yes | No |
| 43409 | Planned | Demonstrating solutions for studying intermittent medication exposures in diseases with episodic manifestations during pregnancy: application to... | No | No |
| 44505 | Planned | Demonstration study 2.5.5 of the ConcePTION project; Validation of primary source pregnancy exposure and outcomes (pharmacovigilance data) | No | No |
European Federation of Pharmaceutical Industries and Associations (EFPIA)
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
European Federation of Pharmaceutical Industries and Associations (EFPIA)
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
European Federation of Pharmaceutical Industries and Associations (EFPIA)
10 Study countries specified are the following: